US reviews birth control pill safety over clot risk

May 31, 2011

The US Food and Drug Administration said Tuesday it is reviewing recently published studies which have pointed to an increased blood clot risk associated with a certain type of birth control pill.

The studies involve pills that contain drospirenone, as opposed to another type of progestin known as . Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

"The FDA is currently evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone-containing birth control pills," it said in a statement.

"FDA will continue to communicate any new safety information to the public as it becomes available."

The European Medicines Agency concluded on May 27 that such birth control pills carry a higher risk of venous thromboembolism and that should be updated accordingly.

However it noted the overall risk of blood clot from any birth control method remains small and stopped short of advising women to stop taking pills containing drospirenone.

The pills have been the focus of numerous lawsuits, including one lodged earlier this month on behalf of a teenager who died from a blood clot allegedly linked to the German chemical and pharmaceutical company Bayer's Yaz contraceptive.

Michelle Pfleger, an 18-year-old college student in North Carolina, died of cardiac arrest last September after taking YAZ, also known as Yasmin or Ocella, to treat acne, according to the complaint.

Last month, two studies in the found that drugs like Yaz and Yasmin increase the risk of serious blood clots three-fold or two-fold compared to earlier-generation .

Bayer criticized the results of the studies at the time, insisting that side effects were rare.

The official Yaz website says the drug is associated with "increased risks of several serious side effects, including blood clots, stroke, and heart attack."

Explore further: Feds vows to publicize vaccine injury help program

add to favorites email to friend print save as pdf

Related Stories

New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

Non-prescription pills draws controversy

Feb 05, 2007

A new plan in Britain that would allow birth control pills to be available for sale without prescription has some area doctors concerned, a report said.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.